Department of Radiation Oncology, Ludwig-Maximilians-University Munich, München, Germany.
Radiother Oncol. 2011 Jan;98(1):1-14. doi: 10.1016/j.radonc.2010.11.006. Epub 2010 Dec 13.
Despite the given advances in neuro-oncology most patients with high grade malignant glioma ultimately fail locally or locoregionally. In parallel with improvements of initial treatment options, several salvage strategies have been elucidated and already entered clinical practice. Aim of this article is to review the current status of salvage strategies in recurrent high grade glioma.
Using the following MESH headings and combinations of these terms the pubmed database was searched: "Glioma", "Recurrence", "Neoplasm Recurrence, Local", "Radiosurgery", "Brachytherapy", "Neurosurgical Procedures" and "Drug Therapy". For citation crosscheck the ISI web of science database was used employing the same search terms. In parallel, the abstracts of ASCO 2008-2009 were analyzed accordingly.
Currently the following options for salvage entered clinical practice: re-resection, re-irradiation (stereotactic radiosurgery, (hypo-)fractionated (stereotactic) radiotherapy, interstitial brachytherapy) or single/poly-chemotherapy schedules including new dose-intensified or alternative treatment protocols employing targeted drugs. Re-operation is associated with high morbidity and mortality, however, is an option in a highly selected patient cohort. Since toxicity has been overestimated, re-irradiation is an increasingly used option with precise fractionated radiotherapy being the most optimal technique. On average, time to secondary progression is in the range of several months. Conventional chemotherapy regimens also improve time to secondary progression; however the efficacy is only modest and treatment-related toxicities like myelo-suppression occur very frequently. Molecular targeted agents/kinases are undergoing clinical testing; however no final recommendations can be made.
Currently, several re-treatment options with only modest efficacy exist. The relative value of each approach compared to other options is unknown as well as it remains open which sequence of modalities should be chosen.
尽管神经肿瘤学取得了一定的进展,但大多数高级别恶性胶质瘤患者最终仍会出现局部或局部区域复发。随着初始治疗选择的改进,已经阐明了几种挽救策略,并已进入临床实践。本文旨在综述复发性高级别胶质瘤的挽救策略现状。
使用以下 MESH 标题和这些术语的组合,在 pubmed 数据库中进行了搜索:“Glioma”、“Recurrence”、“Neoplasm Recurrence, Local”、“Radiosurgery”、“Brachytherapy”、“Neurosurgical Procedures”和“Drug Therapy”。为了交叉核对引文,使用了 ISI web of science 数据库,采用了相同的搜索条件。同时,还对 2008-2009 年 ASCO 的摘要进行了相应的分析。
目前,以下挽救方案已进入临床实践:再次手术切除、再次放疗(立体定向放射外科、(低)分割(立体定向)放疗、间质近距离放疗)或单一/多化疗方案,包括新的剂量强化或采用靶向药物的替代治疗方案。再次手术切除相关的发病率和死亡率较高,但在高度选择的患者群体中是一种选择。由于毒性被高估,再次放疗是一种越来越被采用的方案,精确分割放疗是最理想的技术。平均而言,继发性进展的时间在几个月的范围内。常规化疗方案也能改善继发性进展的时间;然而,疗效仅适度,且治疗相关毒性如骨髓抑制非常常见。分子靶向药物/激酶正在进行临床测试;然而,目前还不能做出最终建议。
目前,有几种挽救治疗方案,但疗效仅适度。每种方法相对于其他方法的相对价值尚不清楚,也不清楚应该选择哪种治疗方案的顺序。